1661 - The association of spirometric impairment and history of TB: a population based study in Uganda

The ePoster content is available to users who are logged in.<br><br>Please log in and then come back here to use this button.

Presenting Author(s)

Nicole M. Robertson

Medical Student
University of Kentucky College of Medicine, Kentucky
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Co-Author(s)

JP

J. Zachary Porterfield

Assistant Professor
University of Kentucky College of Medicine
Lexington, Kentucky
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
AK

Alex Kayongo

Physician
Makerere University Lung Institute
Kampala, Kampala, Uganda
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
BK

Bruce Kirenga

Professor
Makerere Lung Institute, Makerere University
Kampala, Kampala, Uganda
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
RK

Robert Kalyesubula

Physician
Departments of Medicine and Physiology, Makerere College of Health Sciences
Kampala, Kampala, Uganda
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
WC

William Checkley

Associate Professor
Johns Hopkins University
Baltimore, Maryland
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Alice C. Thornton

Professor
The University of Kentucky
Lexington, Kentucky
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
TS

Trishul Siddharthan

Assistant Professor
Johns Hopkins University
Baltimore, Maryland
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Background: Pulmonary tuberculosis (TB) is the leading infectious cause of death globally with an estimated 1.7 billion people currently infected with Mycobacterium tuberculosis and at risk of developing TB. While the treatment of drug-susceptible pulmonary TB is highly effective, up to 50% of TB survivors have varying degrees of residual pathological and functional conditions potentially leading to chronic sequelae. Post-TB patients have reported respiratory symptoms, reduced quality of life, and increased risk of mortality. The objectives of this study are to describe the prevalence and lung function in individuals with post-TB exposure status in Uganda.

Methods: We performed a secondary data analysis of the Lung Function in Nakaseke and Kampala (LiNK) study, which is a population-based cohort in urban and rural settings in Uganda. Trained fieldworkers randomly selected homes and administered standard questionnaires to adults 35 years or older that were full-time residents of each setting. Prior TB diagnosis and treatment was self-reported by participants.

Results: Among the study population (N = 1559), 50 participants (3.2%) self-reported successfully treated TB. Among this subset of participants 21 (42.0%) were HIV positive, 9 (18.0%) were ever smokers, 6 (12.0%) were current smokers, and no participants had a prior COPD diagnosis. Mean (SD) age and body-mass index (BMI) at enrollment was 48.5 (SD 10.7) years and 22.2 (SD 3.9) kg/m2 respectively. The mean ± SD pre-bronchodilator FEV1/FVC was 72.9% (12.1%) for patients with successfully treated TB and 79.6% (0.08%) (p< 0.0001) for those without prior TB. Within these groups, 30% of patients with successfully treated TB and 9% of patients without prior TB had an FEV1/FVC suggestive of possible COPD. Comparison of FEV1/FVC

Conclusion: We found a high burden of residual effects of pulmonary TB on lung function and development of COPD, potentially increasing the global burden of COPD. Screening for chronic respiratory diseases following successful TB treatment is needed to improve lung function. Further research is needed to study lung function and quality of life in TB survivors in LMICs, where the burden of pulmonary TB is highest.